Seeking Alpha

Wedbush sees big upside for Fate Therapeutics

  • Wedbush starts recently public Fate Therapeutics (FATE) at Outperform.
  • Analyst David Nierengarten is positive on the outlook for ProHema.
  • Price target is $14, representing upside of around 104% from Friday's close.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs